The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A unique model: Partnership between community oncology and pharma for clinical trial enrichment.
 
Shikha Prakash
No Relationships to Disclose
 
Karla Polk
Employment - Mirati Therapeutics
 
Laura Ensley
Employment - Texas Oncology/US Oncology; Texas Oncology/US Oncology
 
Justin Adams
Employment - Texas Oncology
 
Monica Lisi
Employment - Texas Oncology PA
 
Karen Poe
Employment - Texas Oncology
 
Lorraine Brisbin
Employment - Texas Oncology
Leadership - Precision Health Informatics
Stock and Other Ownership Interests - Precision Health Informatics
Honoraria - Genentech
 
Kartik Konduri
Consulting or Advisory Role - Amgen; AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; squibb; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Takeda
 
Andrew Scott Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer